Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 Cysic Cysic +7.96%
#3 Palladium Network Palladium Network +7.69%
#4 clBTC clBTC +4.43%
#5 Orochi Network Orochi Network +3.09%
#6 Fartcoin Fartcoin +2.79%
#7 Wormhole Bridged Wrapped SOL (Sui) Wormhole Bridged Wrapped SOL (Sui) +2.63%
#8 龙虾 (Lobster) 龙虾 (Lobster) +2.44%
#9 GRVT Token GRVT Token +2.25%
#10 Bedrock Bedrock +2.22%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Rank in Stocks #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Share Price
$0.00162013
Last synced: 2025-01-03
Market Cap
$156.25K
Change (1 day)
0.36%
Change (1 year)
0.00%
Country
SE
Trade Cyxone AB (publ) (CYXO)

Category

Healthcare
P/E ratio for Cyxone AB (publ) (CYXO)
P/E ratio as of August 2026 TTM: -0.08
According to Cyxone AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.08. At the end of 2022 the company had a P/E ratio of -1.05.
P/E ratio history for Cyxone AB (publ) from 2015 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.08 -80.52%
2023 -0.42 -59.85%
2022 -1.05 -51.83%
2021 -2.18 -53.86%
2020 -4.73 0.49%
2019 -4.71 -22.28%
2018 -6.05 -73.76%
2017 -23.07 -6.30%
2016 -24.62 -95.15%
2015 -507.85 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -34,388.75%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -38,173.59%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -23,692.54%
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.